Dr. Anthony P. Furnary Joins Echo Therapeutics Medical Advisory Board

Tuesday May 6, 8:00 am ET

FRANKLIN, Mass., May 6 /PRNewswire-FirstCall/ -- Echo Therapeutics (OTC BB: ECTE.OB) today announced that Anthony P. Furnary, M.D. has joined its Medical Advisory Board. Dr. Furnary, a cardiothoracic surgeon and a leading expert in post-operative insulin therapy and regarded as the "father of tight glycemic control," serves as Associate Director of the Albert Starr Academic Center at Providence St. Vincent Medical Center in Portland, Oregon, Director of Cardiovascular Surgical Research at Oregon Medical Laser Center, and Director of the Portland Diabetes Project. Dr. Furnary is the originator of the widely-adopted "Portland Protocol" which presents a method for maintaining blood glucose levels for post-operative patients in the hospital critical care setting through the use of aggressive insulin therapy, effectively reducing the risks of surgery-related death and complications following surgery in patients with diabetes. Dr. Furnary will advise Echo on development of its Symphony(TM) tCGM System, a novel transdermal continuous glucose monitoring (tCGM) system. Symphony is in late-stage clinical development for use in the diabetes home use and hospital critical care markets.

"It is an honor to welcome Dr. Furnary to Echo's Medical Advisory Board. The wealth of knowledge and clinical expertise in tight glycemic control that he brings to the table enhances our abilities to execute our clinical development plan for Symphony," said Patrick T. Mooney, M.D. Chairman and CEO of Echo. "His acceptance of this position speaks volumes about our Company, the strength of our advisors and the effectiveness of our tCGM technology."

"The immediate clinical need for next-generation technology like Echo's Symphony tCGM System is well understood by physicians familiar with emerging technologies to help achieve and maintain tight glycemic control," said Dr. Furnary. "I look forward to working with Echo and contributing to the Company's success through my active role on its Medical Advisory Board."

"We are pleased to add a physician of Dr. Furnary's stature to our Board of recognized leaders focused on Echo's potentially paradigm-changing tCGM technology for in-hospital and at-home continuous glucose monitoring. His long-standing focus on tight glycemic control and leading-edge technologies that advance protocols designed to accomplish that clinical benefit makes his appointment a particularly synergistic fit," said Stanley Nasraway, MD, Director of Surgical Intensive Care Units at Tufts Medical Center and Chairman of Echo's Medical Advisory Board. "Dr. Furnary's contributions will make a difference."

Dr. Furnary's many honors and awards include the Burroughs Wellcome Leadership Award from the American Medical Association and the Upjohn Achievement Award. The Wall Street Journal recognized his team's groundbreaking research in glycemic control by naming Dr. Furnary runner-up in the 2005 medical innovator of the year (second only to the Harvard team that invented automated gene sequencing). He is a fellow of the American Association for Thoracic Surgery, The Society of Thoracic Surgeons, The American College of Surgeons, The American College of Cardiology and The American College of Chest Physicians. Dr. Furnary introduced the Portland Protocol in the early-1990's as a method for maintaining blood glucose levels for post-operative patients through the use of aggressive insulin therapy. Now widely-practiced worldwide, such therapy reduces the risks of surgery-related death and post-surgical complications in patients with diabetes. Before the Portland Protocol was implemented, patients with diabetes faced twice the normal risk of fatal complications following surgery, and four times the risk of major infection.

About Echo Therapeutics

Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company. Echo's Symphony(TM) tCGM System is a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care settings. Echo is also developing a wide range of novel transdermal reformulations of FDA-approved pharmaceutical products using its AzoneTS(TM) drug delivery technology.

Cautionary Statement Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies regarding the efficacy of Echo's Symphony tCGM System and the success of its research, development, and regulatory approval, marketing and distribution plans and strategies. Furthermore, Echo's tCGM systems have not yet been approved for sale. The regulatory approval process for its tCGM systems involves, among other things, successfully completing pilot and pivotal clinical trials and obtaining a premarket approval, or PMA, from the FDA. The PMA process requires Echo to prove the safety and efficacy of its tCGM systems to the FDA's satisfaction. This process can be expensive and uncertain, and there is no guarantee that Echo will be able to submit a PMA for its Symphony tCGM System or that its Symphony tCGM System will be approved for sale by the FDA in any specific timeframe or at all. In addition, clinical testing of Echo's products and eventual commercialization of its products are subject to all of the risks and uncertainties set forth in its periodic reports, including its annual report on Form 10-KSB for the year ended December 31, 2007, filed with the Securities and Exchange Commission.

The foregoing list of factors is not exhaustive. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations Contacts:
Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329

Lilian Stern
Stern Investor Relations
212-362-1200

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Orlando, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com